Synonyms: compound 3 [PMID: 34448571] | TAK020
Compound class:
Synthetic organic
Comment: TAK-020 is a covalent Bruton's tyrosine kinase (BTK) inhibitor [2]. The compound bonds to Cys481 in BTK's ATP binding site. It was designed for potential to treat haematologic malignancies and/or autoimmune diseases.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Phase 1 safety and tolerability studies have been completed (September 2021). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02723201 | TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants | Phase 1 Interventional | Takeda | ||
NCT02413255 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers | Phase 1 Interventional | Takeda | 1 |